Cancer Biomarkers Market by Profiling Technology (Omics, Imaging), Cancer (Lung, Breast, Leukemia, Melanoma), Product (Instruments, Consumables), Application (Diagnostics, R&D), End User (Diagnostic Laboratories), And Region - Global Forecast to 2032
The market for cancer biomarkers is valued at around USD 28.25 billion in 2026 and is forecast to reach USD 54.48 billion by 2032, representing a growth of 11.6%. The market is growing steadily, and hospitals and diagnostic laboratories are focusing on the early detection and accurate diagnosis of diseases to improve patient outcomes. Factors such as rapid technological advances and the global rise in cancer incidence propel market expansion in the development of cancer biomarkers. However, the main obstacles to this market's expansion are the difficulties in validating cancer biomarkers and the lack of qualified workers.
“The omics technology segment is predicted to showcase the highest CAGR during the forecast period.”
The market for cancer biomarkers has been divided into two segments based on profiling methods: omics technologies and imaging technologies. Omics technology had the highest compound annual growth rate (CAGR) in 2025. This is explained by the growing use of proteomics and genomics in drug discovery and development, as well as by improved cancer diagnostics.
“The breast cancer segment accounted for the highest growth rate in the cancer biomarkers market, by cancer type, during the forecast period.”
The market for cancer biomarkers is divided into categories according to the type of cancer, including non-Hodgkin's lymphoma, kidney cancer, bladder cancer, thyroid cancer, colorectal cancer, prostate cancer, melanoma, leukemia, and other cancer types. In the market for cancer biomarkers in 2025, the breast cancer category had the fastest growth rate. Advances in technology, the rising global prevalence of cancer, and the development of cancer biomarkers are two important factors driving this segment's growth.
“The diagnostic laboratories segment accounted for the highest share.”
Based on end user, the cancer biomarkers market is segmented into diagnostic laboratories, biopharmaceutical companies & CROs, research and academic institutes, and other end-users. In 2025, the diagnostic laboratories segment accounted for a larger share of the cancer biomarkers market. The growing number of clinical laboratories worldwide performing cancer biomarker-based diagnostic tests and the rising prevalence of malignancies are responsible for this end-user segment's sizable share.
“Asia Pacific is expected to register the fastest growth rate in the cancer biomarkers market, by region.”
The region is witnessing a growth spurt due to several key factors, including expanded healthcare infrastructure, increased healthcare expenditure, and greater modernization of hospital and diagnostic facilities. In addition, rising cancer cases and technological advancements in cancer biomarker development are driving growth in the cancer biomarker market in the Asia Pacific region.
The break-up of profiles of primary participants in the cancer biomarkers market:
Research Coverage:
This research report categorizes the cancer biomarkers market by profiling technology (omics technologies, imaging technologies), cancer type (breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-Hodgkin’s lymphoma (NHL), kidney, and other cancers), product type (consumables, instruments, and bioinformatics software), application (diagnostics, research & development, prognostics, risk assessment), end user (diagnostic laboratories, biopharmaceutical companies & CROs, research and academic institutes), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the cancer biomarkers market. A detailed analysis of the key industry players has been conducted to provide insights into their business overviews, solutions, key strategies such as partnerships, collaborations, expansions, agreements, new product launches, and recent developments in the cancer biomarkers market. This report covers a competitive analysis of upcoming startups in the cancer biomarker market ecosystem.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall cancer biomarkers market and the subsegments. It will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
“The omics technology segment is predicted to showcase the highest CAGR during the forecast period.”
The market for cancer biomarkers has been divided into two segments based on profiling methods: omics technologies and imaging technologies. Omics technology had the highest compound annual growth rate (CAGR) in 2025. This is explained by the growing use of proteomics and genomics in drug discovery and development, as well as by improved cancer diagnostics.
“The breast cancer segment accounted for the highest growth rate in the cancer biomarkers market, by cancer type, during the forecast period.”
The market for cancer biomarkers is divided into categories according to the type of cancer, including non-Hodgkin's lymphoma, kidney cancer, bladder cancer, thyroid cancer, colorectal cancer, prostate cancer, melanoma, leukemia, and other cancer types. In the market for cancer biomarkers in 2025, the breast cancer category had the fastest growth rate. Advances in technology, the rising global prevalence of cancer, and the development of cancer biomarkers are two important factors driving this segment's growth.
“The diagnostic laboratories segment accounted for the highest share.”
Based on end user, the cancer biomarkers market is segmented into diagnostic laboratories, biopharmaceutical companies & CROs, research and academic institutes, and other end-users. In 2025, the diagnostic laboratories segment accounted for a larger share of the cancer biomarkers market. The growing number of clinical laboratories worldwide performing cancer biomarker-based diagnostic tests and the rising prevalence of malignancies are responsible for this end-user segment's sizable share.
“Asia Pacific is expected to register the fastest growth rate in the cancer biomarkers market, by region.”
The region is witnessing a growth spurt due to several key factors, including expanded healthcare infrastructure, increased healthcare expenditure, and greater modernization of hospital and diagnostic facilities. In addition, rising cancer cases and technological advancements in cancer biomarker development are driving growth in the cancer biomarker market in the Asia Pacific region.
The break-up of profiles of primary participants in the cancer biomarkers market:
- By Company Type: Tier 1 - 26%, Tier 2 - 44%, and Tier - 30%
- By Designation: C-level - 30%, D-level - 34%, and Others - 36%
- By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America –5 %, Middle East & Africa- 4%, GCC Countries- 1%
Research Coverage:
This research report categorizes the cancer biomarkers market by profiling technology (omics technologies, imaging technologies), cancer type (breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-Hodgkin’s lymphoma (NHL), kidney, and other cancers), product type (consumables, instruments, and bioinformatics software), application (diagnostics, research & development, prognostics, risk assessment), end user (diagnostic laboratories, biopharmaceutical companies & CROs, research and academic institutes), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the cancer biomarkers market. A detailed analysis of the key industry players has been conducted to provide insights into their business overviews, solutions, key strategies such as partnerships, collaborations, expansions, agreements, new product launches, and recent developments in the cancer biomarkers market. This report covers a competitive analysis of upcoming startups in the cancer biomarker market ecosystem.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall cancer biomarkers market and the subsegments. It will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (Technological advancements in cancer biomarkers, increasing incidence of cancer, growing adoption of cancer biomarkers in drug discovery and development, increasing investments in research and development for biomarker innovation, growing adoption of non-invasive diagnostics (liquid biopsy), supportive government initiatives and cancer awareness programs), restraints (High capital requirements and long development timelines for biomarker commercialization, unfavorable regulatory frameworks and reimbursement limitations, high cost of biomarker-based diagnostic tests), opportunities (Expanding role of personalized and precision medicine, increasing applications of companion diagnostics in oncology, growth potential in emerging economies, integration of AI and multi-omics approaches in biomarker discovery and analysis), and challenges (Technical challenges related to sample collection, handling, and storage, complexities associated with biomarker validation and standardization, shortage of skilled professionals and technical expertise) influencing the growth of the cancer biomarkers market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the cancer biomarkers market
- Market Development: Comprehensive information about lucrative markets – the report analyzes the cancer biomarker market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cancer biomarkers market
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING MARKET
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 CANCER BIOMARKERS MARKET OVERVIEW
3.2 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY
3.3 CANCER BIOMARKERS MARKET, BY CANCER TYPE
3.4 CANCER BIOMARKERS MARKET, BY PRODUCT
3.5 CANCER BIOMARKERS MARKET, BY APPLICATION
3.6 CANCER BIOMARKERS MARKET, BY END USER
3.7 CANCER BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Technological Advancements in Cancer Biomarkers
4.2.1.2 Increasing incidence of cancer
4.2.1.3 Growing adoption of cancer biomarkers in drug discovery and development
4.2.1.4 Increasing investments in research and development for biomarker innovation
4.2.1.5 Growing Adoption of Non-Invasive Diagnostics (Liquid Biopsy)
4.2.1.6 Supportive Government Initiatives and Cancer Awareness Programs
4.2.2 RESTRAINTS
4.2.2.1 High capital requirements and long development timelines for biomarker commercialization
4.2.2.2 Unfavorable regulatory frameworks and reimbursement limitations
4.2.2.3 High Cost of Biomarker-Based Diagnostic Tests
4.2.3 OPPORTUNITIES
4.2.3.1 Expanding role of personalized and precision medicine
4.2.3.2 Increasing applications of companion diagnostics in oncology
4.2.3.3 Growth potential in emerging economies
4.2.3.4 Integration of AI and Multi-Omics Approaches in Biomarker Discovery and Analysis
4.2.4 CHALLENGES
4.2.4.1 Technical challenges related to sample collection, handling, and storage
4.2.4.2 Complexities associated with biomarker validation and standardization
4.2.4.3 Shortage of skilled professionals and technical expertise
4.3 UNMET NEEDS AND WHITE SPACES
4.3.1 UNMET NEEDS IN CANCER BIOMARKERS MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 KEY MOVES AND STRATEGIC FOCUS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 BARGAINING POWER OF SUPPLIERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 SINTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.3 SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE OF CANCER BIOMARKERS, BY KEY PLAYER, 2024–2026
5.6.2 AVERAGE SELLING PRICE OF CANCER BIOMARKERS PRODUCTS, BY REGION, 2024–2026
5.7 TRADE ANALYSIS
5.7.1 IMPORT SCENARIO (HS CODE 382200)
5.7.2 EXPORT SCENARIO (HS CODE 382200)
5.8 KEY CONFERENCES & EVENTS, 2026–2027
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10 INVESTMENT & FUNDING SCENARIO
5.11 IMPACT OF 2025 US TARIFF ON CANCER BIOMARKERS MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON REGION
5.11.4.1 North America
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 Diagnostic Laboratories
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 NEXT-GENERATION SEQUENCING
6.1.2 POLYMERASE CHAIN REACTION
6.1.3 IMMUNOASSAYS
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 BIOINFORMATICS PLATFORMS
6.2.2 MASS SPECTROMETRY
6.3 ADJACENT TECHNOLOGIES
6.3.1 LIQUID BIOPSY TECHNOLOGIES
6.3.2 MICROARRAY TECHNOLOGIES
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.5.1 LIST OF KEY PATENTS
6.6 FUTURE APPLICATIONS
6.7 IMPACT OF AI/GENERATIVE AI ON CANCER BIOMARKERS MARKET
6.7.1 INTRODUCTION
6.7.2 TOP USE CASES AND MARKET POTENTIAL
6.7.3 KEY COMPANIES IMPLEMENTING AI
6.7.4 FUTURE OF AI
7 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
7.1 DECISION-MAKING PROCESS
7.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
7.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
7.2.2 BUYING CRITERIA
7.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
7.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
7.5 MARKET PROFITABILITY
7.5.1 REVENUE POTENTIAL
7.5.2 COST DYNAMICS
7.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS
8 CANCER BIOMARKERS MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
8.2 OMICS TECHNOLOGIES
8.2.1 PROTEOMICS
8.2.1.1 Immunoassays
8.2.1.1.1 Facilitate diagnosis of cancer at early stage
8.2.1.2 Mass spectrometry
8.2.1.2.1 High specificity of mass spectroscopy to drive adoption
8.2.1.3 2D gel electrophoresis
8.2.1.3.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive segment
8.2.1.4 Protein microarrays
8.2.1.4.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive growth
8.2.1.5 Other proteomic technologies
8.2.2 GENOMICS
8.2.2.1 Next-generation sequencing
8.2.2.1.1 Development of advanced NGS platforms by leading players to drive growth
8.2.2.2 Polymerase chain reaction
8.2.2.2.1 Cost-effectiveness and easy availability of PCR tests to propel market
8.2.2.3 In situ hybridization
8.2.2.3.1 ISH-based diagnostic tests help identify specific biomarkers in clinical trials
8.2.3 OTHER OMICS TECHNOLOGIES
8.3 IMAGING TECHNOLOGIES
8.3.1 ULTRASOUND IMAGING
8.3.1.1 Use of ultrasound for biomarker research in understanding disease onset & progression to drive growth
8.3.2 COMPUTED TOMOGRAPHY
8.3.2.1 Technological advancements to drive adoption
8.3.3 MAGNETIC RESONANCE IMAGING
8.3.3.1 Growing preference for open MRIs to support market growth
8.3.4 POSITRON EMISSION TOMOGRAPHY
8.3.4.1 Development of lab-on-chip-based multiplex assays to propel market
8.3.5 MAMMOGRAPHY
8.3.5.1 Advanced technologies like 3D mammography to support market growth
9 CANCER BIOMARKERS MARKET, BY CANCER TYPE
9.1 INTRODUCTION
9.2 BREAST CANCER
9.2.1 INCREASING PREVALENCE OF BREAST CANCER TO DRIVE MARKET
9.3 LUNG CANCER
9.3.1 INCREASING FOCUS ON DEVELOPMENT OF LUNG CANCER BIOMARKERS TO SUPPORT MARKET GROWTH
9.4 COLORECTAL CANCER
9.4.1 RISING DEMAND FOR BIOMARKERS IN EARLY DIAGNOSIS & PROGNOSIS OF COLORECTAL CANCER TO DRIVE MARKET
9.5 PROSTATE CANCER
9.5.1 ADVANCEMENTS IN GENOMIC TECHNOLOGIES TO PROPEL MARKET
9.6 MELANOMA
9.6.1 INCREASING UTILIZATION OF DIAGNOSTICS IN BRAF INHIBITOR THERAPY TO DRIVE MARKET
9.7 LEUKEMIA
9.7.1 INCREASING NUMBER OF RESEARCH STUDIES FOR DEVELOPMENT OF ACCURATE DIAGNOSTIC METHODS FOR LEUKEMIA TO DRIVE MARKET
9.8 THYROID CANCER
9.8.1 INCREASING RESEARCH FOR IDENTIFICATION OF NEW BIOMARKERS FOR THYROID NODULES TO SUPPORT MARKET GROWTH
9.9 BLADDER CANCER
9.9.1 INCREASING APPROVALS OF URINARY BIOMARKERS FOR DETECTION OF BLADDER CANCER TO PROPEL MARKET
9.10 NON-HODGKIN’S LYMPHOMA
9.10.1 INCREASING RESEARCH ACTIVITIES ON NHL TO DRIVE MARKET
9.11 KIDNEY CANCER
9.11.1 DEVELOPMENT OF NEW TARGETED THERAPIES FOR TREATMENT OF KIDNEY CANCER TO DRIVE MARKET
9.12 OTHER CANCERS
10 CANCER BIOMARKERS MARKET, BY PRODUCT
10.1 INTRODUCTION
10.2 CONSUMABLES
10.2.1 KITS & REAGENTS
10.2.1.1 Ease of use to support adoption
10.2.2 ANTIBODIES
10.2.2.1 Increasing approvals for therapeutic antibodies by regulatory authorities to drive market
10.2.3 PROBES
10.2.3.1 Need for probes in assay tests for cancer detection to support market growth
10.3 INSTRUMENTS
10.3.1 IMAGING INSTRUMENTS
10.3.1.1 Technological advancements in imaging instruments to drive growth
10.3.2 PATHOLOGY-BASED INSTRUMENTS
10.3.2.1 Rising demand for cancer diagnosis to drive market
10.3.3 BIOPSY INSTRUMENTS
10.3.3.1 Increasing prevalence of cancer to drive growth
10.4 BIOINFORMATICS SOFTWARE
10.4.1 TECHNOLOGICAL ADVANCEMENTS AND GROWING INFORMATION TECHNOLOGY SECTOR TO DRIVE MARKET
11 CANCER BIOMARKERS MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 DIAGNOSTICS
11.2.1 INCREASED AWARENESS & ACCEPTANCE OF TECHNOLOGICALLY ADVANCED BIOMARKER PRODUCTS TO PROPEL MARKET
11.3 RESEARCH & DEVELOPMENT
11.3.1 INCREASING FOCUS OF PHARMACEUTICAL COMPANIES ON USE OF BIOMARKERS IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
11.4 PROGNOSTICS
11.4.1 GROWING ADOPTION OF SPECIFIC AND SENSITIVE BIOMARKER TESTS TO SUPPORT MARKET GROWTH
11.5 RISK ASSESSMENT
11.5.1 USED FOR DETECTING MUTATIONS OR VARIANTS IN GERMLINE DNA OF INDIVIDUALS
11.6 OTHER APPLICATIONS
12 CANCER BIOMARKERS MARKET, BY END USER
12.1 INTRODUCTION
12.2 DIAGNOSTIC LABORATORIES
12.2.1 INCREASING INCIDENCE OF CANCER TO DRIVE GROWTH
12.3 BIOPHARMACEUTICAL COMPANIES AND CROS
12.3.1 RISING FOCUS ON DRUG DISCOVERY IN BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DRIVE MARKET
12.4 RESEARCH AND ACADEMIC INSTITUTES
12.4.1 INCREASING RESEARCH FUNDING FOR EARLY DIAGNOSIS TO AUGMENT MARKET
12.5 OTHER END USERS
13 CANCER BIOMARKERS MARKET, BY REGION
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 US
13.2.1.1 High adoption of precision oncology and biomarker-driven therapies to drive market growth
13.2.2 CANADA
13.2.2.1 Government Initiatives Driving Biomarker Growth
13.3 EUROPE
13.3.1 GERMANY
13.3.1.1 High Healthcare Spending Driving Biomarker Adoption
13.3.2 UK
13.3.2.1 Rising Cancer Incidence Driving Biomarker Adoption
13.3.3 FRANCE
13.3.3.1 Government Funding Supporting Biomarker Market Growth
13.3.4 ITALY
13.3.4.1 Growing geriatric population to support market growth
13.3.5 SPAIN
13.3.5.1 Rising emphasis on personalized medicine to drive market growth
13.3.6 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 CHINA
13.4.1.1 Rising cancer burden and strong government support to drive market growth
13.4.2 JAPAN
13.4.2.1 Strong healthcare investment to drive market growth
13.4.3 INDIA
13.4.3.1 Rising cancer burden and expanding healthcare investments to drive market growth
13.4.4 AUSTRALIA
13.4.4.1 Rising cancer burden and strong government investments to drive market growth
13.4.5 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 BRAZIL
13.5.1.1 Rising cancer incidence to drive market growth
13.5.2 MEXICO
13.5.2.1 Expanding healthcare access and rising cancer burden to drive market growth
13.5.3 REST OF LATIN AMERICA
13.6 MIDDLE EAST & AFRICA
13.6.1 EMERGING PRECISION MEDICINE INITIATIVES TO DRIVE MARKET GROWTH
13.7 GCC COUNTRIES
13.7.1 EXPANDING HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET GROWTH
14 COMPETITIVE LANDSCAPE
14.1 INTRODUCTION
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CANCER BIOMARKERS MARKET
14.3 REVENUE ANALYSIS, 2023–2025
14.4 MARKET SHARE ANALYSIS, 2025
14.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
14.4.2 US: MARKET SHARE ANALYSIS, 2025
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
14.5.1 STARS
14.5.2 EMERGING LEADERS
14.5.3 PERVASIVE PLAYERS
14.5.4 PARTICIPANTS
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
14.5.5.1 Company footprint
14.5.5.2 Regional footprint
14.5.5.3 Product footprint
14.5.5.4 Profiling Technology footprint
14.5.5.5 Application footprint
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
14.6.1 PROGRESSIVE COMPANIES
14.6.2 RESPONSIVE COMPANIES
14.6.3 DYNAMIC COMPANIES
14.6.4 STARTING BLOCKS
14.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
14.6.5.1 Detailed list of key startups/SMEs
14.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
14.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
14.7 COMPANY VALUATION & FINANCIAL METRICS
14.7.1 FINANCIAL METRICS
14.7.2 COMPANY VALUATION
14.8 BRAND/PRODUCT COMPARISON
14.9 COMPETITIVE SCENARIO
14.9.1 PRODUCT LAUNCHES & APPROVALS
14.9.2 DEALS
15 COMPANY PROFILES
15.1 KEY PLAYERS
15.1.1 F. HOFFMANN-LA ROCHE AG
15.1.1.1 Business overview
15.1.1.2 Products offered
15.1.1.3 Recent developments
15.1.1.3.1 Product launches & approvals
15.1.1.3.2 Deals
15.1.1.4 MnM view
15.1.1.4.1 Key strengths
15.1.1.4.2 Strategic choices
15.1.1.4.3 Weaknesses and competitive threats
15.1.2 THERMO FISHER SCIENTIFIC
15.1.2.1 Business overview
15.1.2.2 Products offered
15.1.2.3 Recent developments
15.1.2.3.1 Product launches & approvals
15.1.2.3.2 Deals
15.1.2.4 MnM view
15.1.2.4.1 Key strengths
15.1.2.4.2 Strategic choices
15.1.2.4.3 Weaknesses & competitive threats
15.1.3 ILLUMINA, INC.
15.1.3.1 Business overview
15.1.3.2 Products & services offered
15.1.3.3 Recent developments
15.1.3.3.1 Product launches & approvals
15.1.3.3.2 Deals
15.1.3.4 MnM view
15.1.3.4.1 Key strengths
15.1.3.4.2 Strategic choices
15.1.3.4.3 Weaknesses and competitive threats
15.1.4 AGILENT TECHNOLOGIES, INC.
15.1.4.1 Business overview
15.1.4.2 Products & services offered
15.1.4.3 Recent developments
15.1.4.3.1 Product launches & approvals
15.1.4.3.2 Deals
15.1.4.4 MnM view
15.1.4.4.1 Key strengths
15.1.4.4.2 Strategic choices
15.1.4.4.3 Weaknesses and competitive threats
15.1.5 QIAGEN
15.1.5.1 Business overview
15.1.5.2 Products & services offered
15.1.5.3 Recent developments
15.1.5.3.1 Product launches & approvals
15.1.5.3.2 Deals
15.1.5.4 MnM view
15.1.5.4.1 Key strengths
15.1.5.4.2 Strategic choices
15.1.5.4.3 Weaknesses & competitive threats
15.1.6 BIO-RAD LABORATORIES, INC.
15.1.6.1 Business overview
15.1.6.2 Products & services offered
15.1.6.3 Recent developments
15.1.6.3.1 Deals
15.1.7 DANAHER CORPORATION
15.1.7.1 Business overview
15.1.7.2 Products offered
15.1.8 ABBOTT LABORATORIES
15.1.8.1 Business overview
15.1.8.2 Products offered
15.1.8.3 Recent developments
15.1.8.3.1 Deals
15.1.9 BIOM?RIEUX
15.1.9.1 Business overview
15.1.9.2 Products & services offered
15.1.10 MERCK KGAA
15.1.10.1 Business overview
15.1.10.2 Products & services offered
15.1.10.3 Recent developments
15.1.10.3.1 Product launches & approvals
15.1.11 SIEMENS HEALTHINEERS AG
15.1.11.1 Business overview
15.1.11.2 Products offered
15.1.12 BECTON, DICKINSON AND COMPANY
15.1.12.1 Business overview
15.1.12.2 Products offered
15.2 OTHER PLAYERS
15.2.1 MYRIAD GENETICS
15.2.2 SYSMEX CORPORATION
15.2.3 HOLOGIC, INC.
15.2.4 QUEST DIAGNOSTICS
15.2.5 CENTOGENE N.V.
15.2.6 BIOGENEX
15.2.7 R&D SYSTEMS, INC.
15.2.8 BIOVISION INC.
15.2.9 OLINK
15.2.10 ASURAGEN, INC.
15.2.11 MESO SCALE DIAGNOSTICS, LLC
15.2.12 INVIVOSCRIBE, INC.
15.2.13 INOVIQ LTD.
15.2.14 NANTOMICS
16 RESEARCH METHODOLOGY
16.1 RESEARCH DATA
16.1.1 SECONDARY DATA
16.1.1.1 List of secondary sources
16.1.1.2 Key data from secondary sources
16.1.2 PRIMARY DATA
16.1.2.1 List of primary sources
16.1.2.2 Key data from primary sources
16.1.2.3 Key industry insights
16.1.2.4 Breakdown of primary interviews
16.2 MARKET SIZE ESTIMATION
16.2.1 TOTAL MARKET SIZE: CANCER BIOMARKERS MARKET
16.2.2 BOTTOM-UP APPROACH
16.2.2.1 Approach 1: Revenue estimation of key players
16.2.2.2 Approach 2: Study of annual reports and investor presentations
16.2.2.3 Approach 3: Primary interviews
16.2.2.4 Growth forecast
16.2.2.5 CAGR projections
16.2.3 TOP-DOWN APPROACH
16.3 DATA TRIANGULATION
16.4 RESEARCH ASSUMPTIONS
16.4.1 STUDY-RELATED ASSUMPTIONS
16.5 STUDY ASSUMPTIONS
16.5.1 PARAMETRIC ASSUMPTIONS
16.5.2 GROWTH RATE ASSUMPTIONS
16.6 RESEARCH LIMITATIONS
16.7 RISK ASSESSMENT
17 APPENDIX
17.1 DISCUSSION GUIDE
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
17.3 CUSTOMIZATION OPTIONS
17.4 RELATED REPORTS
17.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING MARKET
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 CANCER BIOMARKERS MARKET OVERVIEW
3.2 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY
3.3 CANCER BIOMARKERS MARKET, BY CANCER TYPE
3.4 CANCER BIOMARKERS MARKET, BY PRODUCT
3.5 CANCER BIOMARKERS MARKET, BY APPLICATION
3.6 CANCER BIOMARKERS MARKET, BY END USER
3.7 CANCER BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Technological Advancements in Cancer Biomarkers
4.2.1.2 Increasing incidence of cancer
4.2.1.3 Growing adoption of cancer biomarkers in drug discovery and development
4.2.1.4 Increasing investments in research and development for biomarker innovation
4.2.1.5 Growing Adoption of Non-Invasive Diagnostics (Liquid Biopsy)
4.2.1.6 Supportive Government Initiatives and Cancer Awareness Programs
4.2.2 RESTRAINTS
4.2.2.1 High capital requirements and long development timelines for biomarker commercialization
4.2.2.2 Unfavorable regulatory frameworks and reimbursement limitations
4.2.2.3 High Cost of Biomarker-Based Diagnostic Tests
4.2.3 OPPORTUNITIES
4.2.3.1 Expanding role of personalized and precision medicine
4.2.3.2 Increasing applications of companion diagnostics in oncology
4.2.3.3 Growth potential in emerging economies
4.2.3.4 Integration of AI and Multi-Omics Approaches in Biomarker Discovery and Analysis
4.2.4 CHALLENGES
4.2.4.1 Technical challenges related to sample collection, handling, and storage
4.2.4.2 Complexities associated with biomarker validation and standardization
4.2.4.3 Shortage of skilled professionals and technical expertise
4.3 UNMET NEEDS AND WHITE SPACES
4.3.1 UNMET NEEDS IN CANCER BIOMARKERS MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 KEY MOVES AND STRATEGIC FOCUS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 BARGAINING POWER OF SUPPLIERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 SINTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.3 SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE OF CANCER BIOMARKERS, BY KEY PLAYER, 2024–2026
5.6.2 AVERAGE SELLING PRICE OF CANCER BIOMARKERS PRODUCTS, BY REGION, 2024–2026
5.7 TRADE ANALYSIS
5.7.1 IMPORT SCENARIO (HS CODE 382200)
5.7.2 EXPORT SCENARIO (HS CODE 382200)
5.8 KEY CONFERENCES & EVENTS, 2026–2027
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10 INVESTMENT & FUNDING SCENARIO
5.11 IMPACT OF 2025 US TARIFF ON CANCER BIOMARKERS MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON REGION
5.11.4.1 North America
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 Diagnostic Laboratories
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 NEXT-GENERATION SEQUENCING
6.1.2 POLYMERASE CHAIN REACTION
6.1.3 IMMUNOASSAYS
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 BIOINFORMATICS PLATFORMS
6.2.2 MASS SPECTROMETRY
6.3 ADJACENT TECHNOLOGIES
6.3.1 LIQUID BIOPSY TECHNOLOGIES
6.3.2 MICROARRAY TECHNOLOGIES
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.5.1 LIST OF KEY PATENTS
6.6 FUTURE APPLICATIONS
6.7 IMPACT OF AI/GENERATIVE AI ON CANCER BIOMARKERS MARKET
6.7.1 INTRODUCTION
6.7.2 TOP USE CASES AND MARKET POTENTIAL
6.7.3 KEY COMPANIES IMPLEMENTING AI
6.7.4 FUTURE OF AI
7 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
7.1 DECISION-MAKING PROCESS
7.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
7.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
7.2.2 BUYING CRITERIA
7.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
7.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
7.5 MARKET PROFITABILITY
7.5.1 REVENUE POTENTIAL
7.5.2 COST DYNAMICS
7.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS
8 CANCER BIOMARKERS MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
8.2 OMICS TECHNOLOGIES
8.2.1 PROTEOMICS
8.2.1.1 Immunoassays
8.2.1.1.1 Facilitate diagnosis of cancer at early stage
8.2.1.2 Mass spectrometry
8.2.1.2.1 High specificity of mass spectroscopy to drive adoption
8.2.1.3 2D gel electrophoresis
8.2.1.3.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive segment
8.2.1.4 Protein microarrays
8.2.1.4.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive growth
8.2.1.5 Other proteomic technologies
8.2.2 GENOMICS
8.2.2.1 Next-generation sequencing
8.2.2.1.1 Development of advanced NGS platforms by leading players to drive growth
8.2.2.2 Polymerase chain reaction
8.2.2.2.1 Cost-effectiveness and easy availability of PCR tests to propel market
8.2.2.3 In situ hybridization
8.2.2.3.1 ISH-based diagnostic tests help identify specific biomarkers in clinical trials
8.2.3 OTHER OMICS TECHNOLOGIES
8.3 IMAGING TECHNOLOGIES
8.3.1 ULTRASOUND IMAGING
8.3.1.1 Use of ultrasound for biomarker research in understanding disease onset & progression to drive growth
8.3.2 COMPUTED TOMOGRAPHY
8.3.2.1 Technological advancements to drive adoption
8.3.3 MAGNETIC RESONANCE IMAGING
8.3.3.1 Growing preference for open MRIs to support market growth
8.3.4 POSITRON EMISSION TOMOGRAPHY
8.3.4.1 Development of lab-on-chip-based multiplex assays to propel market
8.3.5 MAMMOGRAPHY
8.3.5.1 Advanced technologies like 3D mammography to support market growth
9 CANCER BIOMARKERS MARKET, BY CANCER TYPE
9.1 INTRODUCTION
9.2 BREAST CANCER
9.2.1 INCREASING PREVALENCE OF BREAST CANCER TO DRIVE MARKET
9.3 LUNG CANCER
9.3.1 INCREASING FOCUS ON DEVELOPMENT OF LUNG CANCER BIOMARKERS TO SUPPORT MARKET GROWTH
9.4 COLORECTAL CANCER
9.4.1 RISING DEMAND FOR BIOMARKERS IN EARLY DIAGNOSIS & PROGNOSIS OF COLORECTAL CANCER TO DRIVE MARKET
9.5 PROSTATE CANCER
9.5.1 ADVANCEMENTS IN GENOMIC TECHNOLOGIES TO PROPEL MARKET
9.6 MELANOMA
9.6.1 INCREASING UTILIZATION OF DIAGNOSTICS IN BRAF INHIBITOR THERAPY TO DRIVE MARKET
9.7 LEUKEMIA
9.7.1 INCREASING NUMBER OF RESEARCH STUDIES FOR DEVELOPMENT OF ACCURATE DIAGNOSTIC METHODS FOR LEUKEMIA TO DRIVE MARKET
9.8 THYROID CANCER
9.8.1 INCREASING RESEARCH FOR IDENTIFICATION OF NEW BIOMARKERS FOR THYROID NODULES TO SUPPORT MARKET GROWTH
9.9 BLADDER CANCER
9.9.1 INCREASING APPROVALS OF URINARY BIOMARKERS FOR DETECTION OF BLADDER CANCER TO PROPEL MARKET
9.10 NON-HODGKIN’S LYMPHOMA
9.10.1 INCREASING RESEARCH ACTIVITIES ON NHL TO DRIVE MARKET
9.11 KIDNEY CANCER
9.11.1 DEVELOPMENT OF NEW TARGETED THERAPIES FOR TREATMENT OF KIDNEY CANCER TO DRIVE MARKET
9.12 OTHER CANCERS
10 CANCER BIOMARKERS MARKET, BY PRODUCT
10.1 INTRODUCTION
10.2 CONSUMABLES
10.2.1 KITS & REAGENTS
10.2.1.1 Ease of use to support adoption
10.2.2 ANTIBODIES
10.2.2.1 Increasing approvals for therapeutic antibodies by regulatory authorities to drive market
10.2.3 PROBES
10.2.3.1 Need for probes in assay tests for cancer detection to support market growth
10.3 INSTRUMENTS
10.3.1 IMAGING INSTRUMENTS
10.3.1.1 Technological advancements in imaging instruments to drive growth
10.3.2 PATHOLOGY-BASED INSTRUMENTS
10.3.2.1 Rising demand for cancer diagnosis to drive market
10.3.3 BIOPSY INSTRUMENTS
10.3.3.1 Increasing prevalence of cancer to drive growth
10.4 BIOINFORMATICS SOFTWARE
10.4.1 TECHNOLOGICAL ADVANCEMENTS AND GROWING INFORMATION TECHNOLOGY SECTOR TO DRIVE MARKET
11 CANCER BIOMARKERS MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 DIAGNOSTICS
11.2.1 INCREASED AWARENESS & ACCEPTANCE OF TECHNOLOGICALLY ADVANCED BIOMARKER PRODUCTS TO PROPEL MARKET
11.3 RESEARCH & DEVELOPMENT
11.3.1 INCREASING FOCUS OF PHARMACEUTICAL COMPANIES ON USE OF BIOMARKERS IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
11.4 PROGNOSTICS
11.4.1 GROWING ADOPTION OF SPECIFIC AND SENSITIVE BIOMARKER TESTS TO SUPPORT MARKET GROWTH
11.5 RISK ASSESSMENT
11.5.1 USED FOR DETECTING MUTATIONS OR VARIANTS IN GERMLINE DNA OF INDIVIDUALS
11.6 OTHER APPLICATIONS
12 CANCER BIOMARKERS MARKET, BY END USER
12.1 INTRODUCTION
12.2 DIAGNOSTIC LABORATORIES
12.2.1 INCREASING INCIDENCE OF CANCER TO DRIVE GROWTH
12.3 BIOPHARMACEUTICAL COMPANIES AND CROS
12.3.1 RISING FOCUS ON DRUG DISCOVERY IN BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DRIVE MARKET
12.4 RESEARCH AND ACADEMIC INSTITUTES
12.4.1 INCREASING RESEARCH FUNDING FOR EARLY DIAGNOSIS TO AUGMENT MARKET
12.5 OTHER END USERS
13 CANCER BIOMARKERS MARKET, BY REGION
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 US
13.2.1.1 High adoption of precision oncology and biomarker-driven therapies to drive market growth
13.2.2 CANADA
13.2.2.1 Government Initiatives Driving Biomarker Growth
13.3 EUROPE
13.3.1 GERMANY
13.3.1.1 High Healthcare Spending Driving Biomarker Adoption
13.3.2 UK
13.3.2.1 Rising Cancer Incidence Driving Biomarker Adoption
13.3.3 FRANCE
13.3.3.1 Government Funding Supporting Biomarker Market Growth
13.3.4 ITALY
13.3.4.1 Growing geriatric population to support market growth
13.3.5 SPAIN
13.3.5.1 Rising emphasis on personalized medicine to drive market growth
13.3.6 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 CHINA
13.4.1.1 Rising cancer burden and strong government support to drive market growth
13.4.2 JAPAN
13.4.2.1 Strong healthcare investment to drive market growth
13.4.3 INDIA
13.4.3.1 Rising cancer burden and expanding healthcare investments to drive market growth
13.4.4 AUSTRALIA
13.4.4.1 Rising cancer burden and strong government investments to drive market growth
13.4.5 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 BRAZIL
13.5.1.1 Rising cancer incidence to drive market growth
13.5.2 MEXICO
13.5.2.1 Expanding healthcare access and rising cancer burden to drive market growth
13.5.3 REST OF LATIN AMERICA
13.6 MIDDLE EAST & AFRICA
13.6.1 EMERGING PRECISION MEDICINE INITIATIVES TO DRIVE MARKET GROWTH
13.7 GCC COUNTRIES
13.7.1 EXPANDING HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET GROWTH
14 COMPETITIVE LANDSCAPE
14.1 INTRODUCTION
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CANCER BIOMARKERS MARKET
14.3 REVENUE ANALYSIS, 2023–2025
14.4 MARKET SHARE ANALYSIS, 2025
14.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
14.4.2 US: MARKET SHARE ANALYSIS, 2025
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
14.5.1 STARS
14.5.2 EMERGING LEADERS
14.5.3 PERVASIVE PLAYERS
14.5.4 PARTICIPANTS
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
14.5.5.1 Company footprint
14.5.5.2 Regional footprint
14.5.5.3 Product footprint
14.5.5.4 Profiling Technology footprint
14.5.5.5 Application footprint
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
14.6.1 PROGRESSIVE COMPANIES
14.6.2 RESPONSIVE COMPANIES
14.6.3 DYNAMIC COMPANIES
14.6.4 STARTING BLOCKS
14.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
14.6.5.1 Detailed list of key startups/SMEs
14.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
14.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
14.7 COMPANY VALUATION & FINANCIAL METRICS
14.7.1 FINANCIAL METRICS
14.7.2 COMPANY VALUATION
14.8 BRAND/PRODUCT COMPARISON
14.9 COMPETITIVE SCENARIO
14.9.1 PRODUCT LAUNCHES & APPROVALS
14.9.2 DEALS
15 COMPANY PROFILES
15.1 KEY PLAYERS
15.1.1 F. HOFFMANN-LA ROCHE AG
15.1.1.1 Business overview
15.1.1.2 Products offered
15.1.1.3 Recent developments
15.1.1.3.1 Product launches & approvals
15.1.1.3.2 Deals
15.1.1.4 MnM view
15.1.1.4.1 Key strengths
15.1.1.4.2 Strategic choices
15.1.1.4.3 Weaknesses and competitive threats
15.1.2 THERMO FISHER SCIENTIFIC
15.1.2.1 Business overview
15.1.2.2 Products offered
15.1.2.3 Recent developments
15.1.2.3.1 Product launches & approvals
15.1.2.3.2 Deals
15.1.2.4 MnM view
15.1.2.4.1 Key strengths
15.1.2.4.2 Strategic choices
15.1.2.4.3 Weaknesses & competitive threats
15.1.3 ILLUMINA, INC.
15.1.3.1 Business overview
15.1.3.2 Products & services offered
15.1.3.3 Recent developments
15.1.3.3.1 Product launches & approvals
15.1.3.3.2 Deals
15.1.3.4 MnM view
15.1.3.4.1 Key strengths
15.1.3.4.2 Strategic choices
15.1.3.4.3 Weaknesses and competitive threats
15.1.4 AGILENT TECHNOLOGIES, INC.
15.1.4.1 Business overview
15.1.4.2 Products & services offered
15.1.4.3 Recent developments
15.1.4.3.1 Product launches & approvals
15.1.4.3.2 Deals
15.1.4.4 MnM view
15.1.4.4.1 Key strengths
15.1.4.4.2 Strategic choices
15.1.4.4.3 Weaknesses and competitive threats
15.1.5 QIAGEN
15.1.5.1 Business overview
15.1.5.2 Products & services offered
15.1.5.3 Recent developments
15.1.5.3.1 Product launches & approvals
15.1.5.3.2 Deals
15.1.5.4 MnM view
15.1.5.4.1 Key strengths
15.1.5.4.2 Strategic choices
15.1.5.4.3 Weaknesses & competitive threats
15.1.6 BIO-RAD LABORATORIES, INC.
15.1.6.1 Business overview
15.1.6.2 Products & services offered
15.1.6.3 Recent developments
15.1.6.3.1 Deals
15.1.7 DANAHER CORPORATION
15.1.7.1 Business overview
15.1.7.2 Products offered
15.1.8 ABBOTT LABORATORIES
15.1.8.1 Business overview
15.1.8.2 Products offered
15.1.8.3 Recent developments
15.1.8.3.1 Deals
15.1.9 BIOM?RIEUX
15.1.9.1 Business overview
15.1.9.2 Products & services offered
15.1.10 MERCK KGAA
15.1.10.1 Business overview
15.1.10.2 Products & services offered
15.1.10.3 Recent developments
15.1.10.3.1 Product launches & approvals
15.1.11 SIEMENS HEALTHINEERS AG
15.1.11.1 Business overview
15.1.11.2 Products offered
15.1.12 BECTON, DICKINSON AND COMPANY
15.1.12.1 Business overview
15.1.12.2 Products offered
15.2 OTHER PLAYERS
15.2.1 MYRIAD GENETICS
15.2.2 SYSMEX CORPORATION
15.2.3 HOLOGIC, INC.
15.2.4 QUEST DIAGNOSTICS
15.2.5 CENTOGENE N.V.
15.2.6 BIOGENEX
15.2.7 R&D SYSTEMS, INC.
15.2.8 BIOVISION INC.
15.2.9 OLINK
15.2.10 ASURAGEN, INC.
15.2.11 MESO SCALE DIAGNOSTICS, LLC
15.2.12 INVIVOSCRIBE, INC.
15.2.13 INOVIQ LTD.
15.2.14 NANTOMICS
16 RESEARCH METHODOLOGY
16.1 RESEARCH DATA
16.1.1 SECONDARY DATA
16.1.1.1 List of secondary sources
16.1.1.2 Key data from secondary sources
16.1.2 PRIMARY DATA
16.1.2.1 List of primary sources
16.1.2.2 Key data from primary sources
16.1.2.3 Key industry insights
16.1.2.4 Breakdown of primary interviews
16.2 MARKET SIZE ESTIMATION
16.2.1 TOTAL MARKET SIZE: CANCER BIOMARKERS MARKET
16.2.2 BOTTOM-UP APPROACH
16.2.2.1 Approach 1: Revenue estimation of key players
16.2.2.2 Approach 2: Study of annual reports and investor presentations
16.2.2.3 Approach 3: Primary interviews
16.2.2.4 Growth forecast
16.2.2.5 CAGR projections
16.2.3 TOP-DOWN APPROACH
16.3 DATA TRIANGULATION
16.4 RESEARCH ASSUMPTIONS
16.4.1 STUDY-RELATED ASSUMPTIONS
16.5 STUDY ASSUMPTIONS
16.5.1 PARAMETRIC ASSUMPTIONS
16.5.2 GROWTH RATE ASSUMPTIONS
16.6 RESEARCH LIMITATIONS
16.7 RISK ASSESSMENT
17 APPENDIX
17.1 DISCUSSION GUIDE
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
17.3 CUSTOMIZATION OPTIONS
17.4 RELATED REPORTS
17.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 INCLUSIONS AND EXCLUSIONS
TABLE 2 ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+] ALL CANCERS
TABLE 3 CANCER INCIDENCE, BOTH SEXES, IN 2022
TABLE 4 TIMEFRAME FOR DEVELOPMENT OF BIOMARKERS
TABLE 5 IMPACT OF PORTER’S FIVE FORCES ON CANCER BIOMARKERS MARKET
TABLE 6 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030
TABLE 7 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 8 EUROPE: MACROECONOMIC INDICATORS
TABLE 9 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 10 LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 11 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 12 CANCER BIOMARKERS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 13 AVERAGE SELLING PRICE OF CANCER BIOMARKERS, BY KEY PLAYER, 2024–2026 (USD)
TABLE 14 AVERAGE SELLING PRICE OF CANCER BIOMARKERS PRODUCTS, BY REGION, 2024–2026 (USD)
TABLE 15 IMPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 16 EXPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2024 (USD MILLION)
TABLE 17 CANCER BIOMARKERS MARKET: KEY CONFERENCES AND EVENTS, 2026–2027
TABLE 18 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 19 KEY PATENTS IN CANCER BIOMARKERS MARKET, 2022–2026
TABLE 20 KEY COMPANIES IMPLEMENTING AI IN CANCER BIOMARKERS MARKET
TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%)
TABLE 22 KEY BUYING CRITERIA, BY PRODUCT
TABLE 23 ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 24 CANCER BIOMARKERS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
TABLE 25 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION)
TABLE 26 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION)
TABLE 27 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY REGION, 2024–2032 (USD MILLION)
TABLE 28 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 29 EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 30 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 31 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 32 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION)
TABLE 33 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2024–2032 (USD MILLION)
TABLE 34 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 35 EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 36 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 37 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 38 IMMUNOASSAYS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 39 MASS SPECTROMETRY MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 40 2D GEL ELECTROPHORESIS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 41 PROTEIN MICROARRAYS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 42 OTHER PROTEOMIC TECHNOLOGIES MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 43 CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION)
TABLE 44 CANCER BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2024–2032 (USD MILLION)
TABLE 45 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 46 EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 47 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 48 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 49 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 50 POLYMERASE CHAIN REACTION MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 51 IN SITU HYBRIDIZATION MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 52 CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY REGION, 2024–2032 (USD MILLION)
TABLE 53 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 54 EUROPE: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 55 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 56 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 57 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION)
TABLE 58 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2024–2032 (USD MILLION)
TABLE 59 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 60 EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 61 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 62 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 63 ULTRASOUND IMAGING MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 64 NORTH AMERICA: ULTRASOUND IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 65 EUROPE: ULTRASOUND IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 66 ASIA PACIFIC: ULTRASOUND IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 67 LATIN AMERICA: ULTRASOUND IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 68 COMPUTED TOMOGRAPHY MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 69 NORTH AMERICA: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 70 EUROPE: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 71 ASIA PACIFIC: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 72 LATIN AMERICA: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 73 MAGNETIC RESONANCE IMAGING MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 74 NORTH AMERICA: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 75 EUROPE: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 76 ASIA PACIFIC: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 77 LATIN AMERICA: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 78 POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 79 NORTH AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 80 EUROPE: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 81 ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 82 LATIN AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 83 MAMMOGRAPHY MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 84 NORTH AMERICA: MAMMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 85 EUROPE: MAMMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 86 ASIA PACIFIC: MAMMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 87 LATIN AMERICA: MAMMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 88 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION)
TABLE 89 ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2022 VS. 2040
TABLE 90 BREAST CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 91 NORTH AMERICA: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 92 EUROPE: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 93 ASIA PACIFIC: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 94 LATIN AMERICA: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 95 ESTIMATED NUMBER OF LUNG CANCER CASES, BY REGION, 2022 VS. 2040
TABLE 96 LUNG CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 97 NORTH AMERICA: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 98 EUROPE: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 99 ASIA PACIFIC: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 100 LATIN AMERICA: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 101 ESTIMATED NUMBER OF COLORECTAL CANCER CASES, BY REGION, 2022 VS. 2040
TABLE 102 COLORECTAL CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 103 NORTH AMERICA: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 104 EUROPE: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 105 ASIA PACIFIC: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 106 LATIN AMERICA: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 107 PROSTATE CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 108 NORTH AMERICA: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 109 EUROPE: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 110 ASIA PACIFIC: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 111 LATIN AMERICA: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 112 ESTIMATED NUMBER OF MELANOMA CASES, BY REGION, 2022 VS. 2040
TABLE 113 MELANOMA BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 114 NORTH AMERICA: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 115 EUROPE: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 116 ASIA PACIFIC: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 117 LATIN AMERICA: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 118 LEUKEMIA BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 119 NORTH AMERICA: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 120 EUROPE: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 121 ASIA PACIFIC: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 122 LATIN AMERICA: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 123 THYROID CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 124 NORTH AMERICA: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 125 EUROPE: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 126 ASIA PACIFIC: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 127 LATIN AMERICA: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 128 BLADDER CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 129 NORTH AMERICA: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 130 EUROPE: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 131 ASIA PACIFIC: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 132 LATIN AMERICA: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 133 NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 134 NORTH AMERICA: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 135 EUROPE: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 136 ASIA PACIFIC: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 137 LATIN AMERICA: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 138 KIDNEY CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 139 NORTH AMERICA: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 140 EUROPE: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 141 ASIA PACIFIC: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 142 LATIN AMERICA: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 143 OTHER CANCERS BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 144 NORTH AMERICA: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 145 EUROPE: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 146 ASIA PACIFIC: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 147 LATIN AMERICA: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 148 CANCER BIOMARKERS MARKET, BY PRODUCTS, 2024–2032 (USD MILLION)
TABLE 149 CANCER BIOMARKERS CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION)
TABLE 150 CANCER BIOMARKER CONSUMABLES MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 151 NORTH AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 152 EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 153 ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 154 LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 155 KITS & REAGENTS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 156 NORTH AMERICA: KITS & REAGENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 157 EUROPE: KITS & REAGENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 158 ASIA PACIFIC: KITS & REAGENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 159 LATIN AMERICA: KITS & REAGENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 160 ANTIBODIES MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 161 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 162 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 163 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 164 LATIN AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 165 PROBES MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 166 NORTH AMERICA: PROBES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 167 EUROPE: PROBES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 168 ASIA PACIFIC: PROBES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 169 LATIN AMERICA: PROBES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 170 CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION)
TABLE 171 CANCER BIOMARKER INSTRUMENTS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 172 NORTH AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 173 EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 174 ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 175 LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 176 IMAGING INSTRUMENTS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 177 NORTH AMERICA: IMAGING INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 178 EUROPE: IMAGING INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 179 ASIA PACIFIC: IMAGING INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 180 LATIN AMERICA: IMAGING INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 181 PATHOLOGY-BASED INSTRUMENTS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 182 NORTH AMERICA: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 183 EUROPE: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 184 ASIA PACIFIC: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 185 LATIN AMERICA: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 186 BIOPSY INSTRUMENTS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 187 NORTH AMERICA: BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 188 EUROPE: BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 189 ASIA PACIFIC: BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 190 LATIN AMERICA: BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 191 BIOINFORMATICS SOFTWARE MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 192 NORTH AMERICA: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 193 EUROPE: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 194 ASIA PACIFIC: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 195 LATIN AMERICA: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 196 CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 197 CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY REGION, 2024–2032 (USD MILLION)
TABLE 198 NORTH AMERICA: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 199 EUROPE: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 200 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 201 LATIN AMERICA: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 202 CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY REGION, 2024–2032 (USD MILLION)
TABLE 203 NORTH AMERICA: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 204 EUROPE: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 205 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 206 LATIN AMERICA: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 207 CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY REGION, 2024–2032 (USD MILLION)
TABLE 208 NORTH AMERICA: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 209 EUROPE: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 210 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 211 LATIN AMERICA: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 212 CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY REGION, 2024–2032 (USD MILLION)
TABLE 213 NORTH AMERICA: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 214 EUROPE: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 215 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 216 LATIN AMERICA: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 217 CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY REGION, 2024–2032 (USD MILLION)
TABLE 218 NORTH AMERICA: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 219 EUROPE: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 220 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 221 LATIN AMERICA: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 222 CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION)
TABLE 223 CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024–2032 (USD MILLION)
TABLE 224 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 225 EUROPE: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 226 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 227 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 228 CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY REGION, 2024–2032 (USD MILLION)
TABLE 229 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 230 EUROPE: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 231 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 232 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 233 CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2024–2032 (USD MILLION)
TABLE 234 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 235 EUROPE: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 236 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 237 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 238 CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2024–2032 (USD MILLION)
TABLE 239 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 240 EUROPE: CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 241 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 242 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 243 CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 244 NORTH AMERICA: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE
TABLE 245 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 246 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 247 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION)
TABLE 248 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION)
TABLE 249 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION)
TABLE 250 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION)
TABLE 251 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION)
TABLE 252 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION)
TABLE 253 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION)
TABLE 254 NORTH AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION)
TABLE 255 NORTH AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION)
TABLE 256 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION)
TABLE 257 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION)
TABLE 1 INCLUSIONS AND EXCLUSIONS
TABLE 2 ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+] ALL CANCERS
TABLE 3 CANCER INCIDENCE, BOTH SEXES, IN 2022
TABLE 4 TIMEFRAME FOR DEVELOPMENT OF BIOMARKERS
TABLE 5 IMPACT OF PORTER’S FIVE FORCES ON CANCER BIOMARKERS MARKET
TABLE 6 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030
TABLE 7 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 8 EUROPE: MACROECONOMIC INDICATORS
TABLE 9 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 10 LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 11 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 12 CANCER BIOMARKERS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 13 AVERAGE SELLING PRICE OF CANCER BIOMARKERS, BY KEY PLAYER, 2024–2026 (USD)
TABLE 14 AVERAGE SELLING PRICE OF CANCER BIOMARKERS PRODUCTS, BY REGION, 2024–2026 (USD)
TABLE 15 IMPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 16 EXPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2024 (USD MILLION)
TABLE 17 CANCER BIOMARKERS MARKET: KEY CONFERENCES AND EVENTS, 2026–2027
TABLE 18 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 19 KEY PATENTS IN CANCER BIOMARKERS MARKET, 2022–2026
TABLE 20 KEY COMPANIES IMPLEMENTING AI IN CANCER BIOMARKERS MARKET
TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%)
TABLE 22 KEY BUYING CRITERIA, BY PRODUCT
TABLE 23 ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 24 CANCER BIOMARKERS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
TABLE 25 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION)
TABLE 26 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION)
TABLE 27 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY REGION, 2024–2032 (USD MILLION)
TABLE 28 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 29 EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 30 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 31 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 32 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION)
TABLE 33 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2024–2032 (USD MILLION)
TABLE 34 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 35 EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 36 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 37 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 38 IMMUNOASSAYS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 39 MASS SPECTROMETRY MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 40 2D GEL ELECTROPHORESIS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 41 PROTEIN MICROARRAYS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 42 OTHER PROTEOMIC TECHNOLOGIES MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 43 CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION)
TABLE 44 CANCER BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2024–2032 (USD MILLION)
TABLE 45 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 46 EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 47 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 48 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 49 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 50 POLYMERASE CHAIN REACTION MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 51 IN SITU HYBRIDIZATION MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 52 CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY REGION, 2024–2032 (USD MILLION)
TABLE 53 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 54 EUROPE: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 55 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 56 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 57 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION)
TABLE 58 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2024–2032 (USD MILLION)
TABLE 59 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 60 EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 61 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 62 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 63 ULTRASOUND IMAGING MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 64 NORTH AMERICA: ULTRASOUND IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 65 EUROPE: ULTRASOUND IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 66 ASIA PACIFIC: ULTRASOUND IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 67 LATIN AMERICA: ULTRASOUND IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 68 COMPUTED TOMOGRAPHY MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 69 NORTH AMERICA: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 70 EUROPE: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 71 ASIA PACIFIC: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 72 LATIN AMERICA: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 73 MAGNETIC RESONANCE IMAGING MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 74 NORTH AMERICA: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 75 EUROPE: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 76 ASIA PACIFIC: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 77 LATIN AMERICA: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 78 POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 79 NORTH AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 80 EUROPE: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 81 ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 82 LATIN AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 83 MAMMOGRAPHY MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 84 NORTH AMERICA: MAMMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 85 EUROPE: MAMMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 86 ASIA PACIFIC: MAMMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 87 LATIN AMERICA: MAMMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 88 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION)
TABLE 89 ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2022 VS. 2040
TABLE 90 BREAST CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 91 NORTH AMERICA: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 92 EUROPE: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 93 ASIA PACIFIC: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 94 LATIN AMERICA: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 95 ESTIMATED NUMBER OF LUNG CANCER CASES, BY REGION, 2022 VS. 2040
TABLE 96 LUNG CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 97 NORTH AMERICA: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 98 EUROPE: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 99 ASIA PACIFIC: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 100 LATIN AMERICA: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 101 ESTIMATED NUMBER OF COLORECTAL CANCER CASES, BY REGION, 2022 VS. 2040
TABLE 102 COLORECTAL CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 103 NORTH AMERICA: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 104 EUROPE: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 105 ASIA PACIFIC: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 106 LATIN AMERICA: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 107 PROSTATE CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 108 NORTH AMERICA: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 109 EUROPE: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 110 ASIA PACIFIC: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 111 LATIN AMERICA: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 112 ESTIMATED NUMBER OF MELANOMA CASES, BY REGION, 2022 VS. 2040
TABLE 113 MELANOMA BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 114 NORTH AMERICA: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 115 EUROPE: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 116 ASIA PACIFIC: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 117 LATIN AMERICA: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 118 LEUKEMIA BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 119 NORTH AMERICA: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 120 EUROPE: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 121 ASIA PACIFIC: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 122 LATIN AMERICA: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 123 THYROID CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 124 NORTH AMERICA: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 125 EUROPE: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 126 ASIA PACIFIC: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 127 LATIN AMERICA: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 128 BLADDER CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 129 NORTH AMERICA: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 130 EUROPE: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 131 ASIA PACIFIC: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 132 LATIN AMERICA: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 133 NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 134 NORTH AMERICA: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 135 EUROPE: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 136 ASIA PACIFIC: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 137 LATIN AMERICA: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 138 KIDNEY CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 139 NORTH AMERICA: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 140 EUROPE: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 141 ASIA PACIFIC: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 142 LATIN AMERICA: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 143 OTHER CANCERS BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 144 NORTH AMERICA: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 145 EUROPE: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 146 ASIA PACIFIC: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 147 LATIN AMERICA: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 148 CANCER BIOMARKERS MARKET, BY PRODUCTS, 2024–2032 (USD MILLION)
TABLE 149 CANCER BIOMARKERS CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION)
TABLE 150 CANCER BIOMARKER CONSUMABLES MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 151 NORTH AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 152 EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 153 ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 154 LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 155 KITS & REAGENTS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 156 NORTH AMERICA: KITS & REAGENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 157 EUROPE: KITS & REAGENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 158 ASIA PACIFIC: KITS & REAGENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 159 LATIN AMERICA: KITS & REAGENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 160 ANTIBODIES MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 161 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 162 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 163 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 164 LATIN AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 165 PROBES MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 166 NORTH AMERICA: PROBES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 167 EUROPE: PROBES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 168 ASIA PACIFIC: PROBES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 169 LATIN AMERICA: PROBES MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 170 CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION)
TABLE 171 CANCER BIOMARKER INSTRUMENTS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 172 NORTH AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 173 EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 174 ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 175 LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 176 IMAGING INSTRUMENTS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 177 NORTH AMERICA: IMAGING INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 178 EUROPE: IMAGING INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 179 ASIA PACIFIC: IMAGING INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 180 LATIN AMERICA: IMAGING INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 181 PATHOLOGY-BASED INSTRUMENTS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 182 NORTH AMERICA: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 183 EUROPE: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 184 ASIA PACIFIC: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 185 LATIN AMERICA: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 186 BIOPSY INSTRUMENTS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 187 NORTH AMERICA: BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 188 EUROPE: BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 189 ASIA PACIFIC: BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 190 LATIN AMERICA: BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 191 BIOINFORMATICS SOFTWARE MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 192 NORTH AMERICA: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 193 EUROPE: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 194 ASIA PACIFIC: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 195 LATIN AMERICA: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 196 CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 197 CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY REGION, 2024–2032 (USD MILLION)
TABLE 198 NORTH AMERICA: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 199 EUROPE: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 200 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 201 LATIN AMERICA: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 202 CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY REGION, 2024–2032 (USD MILLION)
TABLE 203 NORTH AMERICA: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 204 EUROPE: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 205 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 206 LATIN AMERICA: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 207 CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY REGION, 2024–2032 (USD MILLION)
TABLE 208 NORTH AMERICA: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 209 EUROPE: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 210 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 211 LATIN AMERICA: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 212 CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY REGION, 2024–2032 (USD MILLION)
TABLE 213 NORTH AMERICA: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 214 EUROPE: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 215 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 216 LATIN AMERICA: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 217 CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY REGION, 2024–2032 (USD MILLION)
TABLE 218 NORTH AMERICA: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 219 EUROPE: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 220 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 221 LATIN AMERICA: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 222 CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION)
TABLE 223 CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024–2032 (USD MILLION)
TABLE 224 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 225 EUROPE: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 226 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 227 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 228 CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY REGION, 2024–2032 (USD MILLION)
TABLE 229 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 230 EUROPE: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 231 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 232 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 233 CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2024–2032 (USD MILLION)
TABLE 234 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 235 EUROPE: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 236 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 237 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 238 CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2024–2032 (USD MILLION)
TABLE 239 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 240 EUROPE: CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 241 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 242 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 243 CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION)
TABLE 244 NORTH AMERICA: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE
TABLE 245 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 246 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION)
TABLE 247 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION)
TABLE 248 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION)
TABLE 249 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION)
TABLE 250 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION)
TABLE 251 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION)
TABLE 252 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION)
TABLE 253 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION)
TABLE 254 NORTH AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION)
TABLE 255 NORTH AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION)
TABLE 256 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION)
TABLE 257 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION)
LIST OF FIGURES
FIGURE 1 CANCER BIOMARKERS MARKET SEGMENTATION
FIGURE 2 STUDY YEARS CONSIDERED
FIGURE 3 KEY INSIGHTS AND MARKET HIGHLIGHTS
FIGURE 4 GLOBAL CANCER BIOMARKERS MARKET, 2024–2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CANCER BIOMARKERS MARKET, 2023–2026
FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF CANCER BIOMARKERS MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN CANCER BIOMARKERS MARKET, 2025
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 9 RISING PREVALENCE OF CANCER TO DRIVE MARKET
FIGURE 10 OMICS TECHNOLOGIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 11 BREAST CANCER SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 12 CONSUMABLES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 13 DIAGNOSTICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 14 DIAGNOSTIC LABORATORIES SEGMENT TO COMMAND LARGEST SHARE DURING FORECAST PERIOD
FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 16 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 17 CANCER BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 18 CANCER BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 19 CANCER BIOMARKERS MARKET: VALUE CHAIN ANALYSIS
FIGURE 20 CANCER BIOMARKERS MARKET: ECOSYSTEM ANALYSIS
FIGURE 21 CANCER BIOMARKERS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 22 NUMBER OF DEALS & FUNDING ACTIVITIES IN CANCER BIOMARKERS MARKET
FIGURE 23 PATENT ANALYSIS FOR CANCER BIOMARKERS, JANUARY 2016–DECEMBER 2025
FIGURE 24 MARKET POTENTIAL OF AI IN CANCER BIOMARKERS MARKET
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
FIGURE 26 KEY BUYING CRITERIA, BY PRODUCT
FIGURE 27 NORTH AMERICA: CANCER BIOMARKERS MARKET SNAPSHOT
FIGURE 28 ASIA PACIFIC: CANCER BIOMARKERS MARKET SNAPSHOT
FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN CANCER BIOMARKERS MARKET, 2023–2025 (USD MILLION)
FIGURE 30 GLOBAL CANCER BIOMARKERS MARKET SHARE ANALYSIS, 2025
FIGURE 31 US: CANCER BIOMARKER MARKET SHARE ANALYSIS, 2025
FIGURE 32 CANCER BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 33 CANCER BIOMARKERS MARKET: COMPANY FOOTPRINT, 2025
FIGURE 34 CANCER BIOMARKER MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 35 EV/EBITDA OF KEY VENDORS, 2026
FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2026
FIGURE 37 CANCER BIOMARKER MARKET: BRAND/PRODUCT COMPARISON FOR CANCER BIOMARKER
FIGURE 38 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2025)
FIGURE 39 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT, 2025
FIGURE 40 ILLUMINA, INC.: COMPANY SNAPSHOT, 2025
FIGURE 41 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT, 2025
FIGURE 42 QIAGEN: COMPANY SNAPSHOT, 2025
FIGURE 43 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT, 2025
FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 45 ABBOTT LABORATORIES: COMPANY SNAPSHOT, 2025
FIGURE 46 BIOM?RIEUX: COMPANY SNAPSHOT (2025)
FIGURE 47 MERCK KGAA: COMPANY SNAPSHOT, 2025
FIGURE 48 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT, 2025
FIGURE 49 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT, 2025
FIGURE 50 RESEARCH DESIGN
FIGURE 51 KEY DATA FROM SECONDARY SOURCES
FIGURE 52 LIST OF PRIMARY SOURCES
FIGURE 53 KEY INDUSTRY INSIGHTS
FIGURE 54 BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 55 APPROACH 1: REVENUE ESTIMATION OF KEY PLAYERS
FIGURE 56 CAGR PROJECTIONS
FIGURE 57 TOP-DOWN APPROACH
FIGURE 58 DATA TRIANGULATION
FIGURE 59 PARAMETRIC ASSUMPTIONS
FIGURE 1 CANCER BIOMARKERS MARKET SEGMENTATION
FIGURE 2 STUDY YEARS CONSIDERED
FIGURE 3 KEY INSIGHTS AND MARKET HIGHLIGHTS
FIGURE 4 GLOBAL CANCER BIOMARKERS MARKET, 2024–2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CANCER BIOMARKERS MARKET, 2023–2026
FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF CANCER BIOMARKERS MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN CANCER BIOMARKERS MARKET, 2025
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 9 RISING PREVALENCE OF CANCER TO DRIVE MARKET
FIGURE 10 OMICS TECHNOLOGIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 11 BREAST CANCER SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 12 CONSUMABLES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 13 DIAGNOSTICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 14 DIAGNOSTIC LABORATORIES SEGMENT TO COMMAND LARGEST SHARE DURING FORECAST PERIOD
FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 16 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 17 CANCER BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 18 CANCER BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 19 CANCER BIOMARKERS MARKET: VALUE CHAIN ANALYSIS
FIGURE 20 CANCER BIOMARKERS MARKET: ECOSYSTEM ANALYSIS
FIGURE 21 CANCER BIOMARKERS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 22 NUMBER OF DEALS & FUNDING ACTIVITIES IN CANCER BIOMARKERS MARKET
FIGURE 23 PATENT ANALYSIS FOR CANCER BIOMARKERS, JANUARY 2016–DECEMBER 2025
FIGURE 24 MARKET POTENTIAL OF AI IN CANCER BIOMARKERS MARKET
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
FIGURE 26 KEY BUYING CRITERIA, BY PRODUCT
FIGURE 27 NORTH AMERICA: CANCER BIOMARKERS MARKET SNAPSHOT
FIGURE 28 ASIA PACIFIC: CANCER BIOMARKERS MARKET SNAPSHOT
FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN CANCER BIOMARKERS MARKET, 2023–2025 (USD MILLION)
FIGURE 30 GLOBAL CANCER BIOMARKERS MARKET SHARE ANALYSIS, 2025
FIGURE 31 US: CANCER BIOMARKER MARKET SHARE ANALYSIS, 2025
FIGURE 32 CANCER BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 33 CANCER BIOMARKERS MARKET: COMPANY FOOTPRINT, 2025
FIGURE 34 CANCER BIOMARKER MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 35 EV/EBITDA OF KEY VENDORS, 2026
FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2026
FIGURE 37 CANCER BIOMARKER MARKET: BRAND/PRODUCT COMPARISON FOR CANCER BIOMARKER
FIGURE 38 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2025)
FIGURE 39 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT, 2025
FIGURE 40 ILLUMINA, INC.: COMPANY SNAPSHOT, 2025
FIGURE 41 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT, 2025
FIGURE 42 QIAGEN: COMPANY SNAPSHOT, 2025
FIGURE 43 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT, 2025
FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 45 ABBOTT LABORATORIES: COMPANY SNAPSHOT, 2025
FIGURE 46 BIOM?RIEUX: COMPANY SNAPSHOT (2025)
FIGURE 47 MERCK KGAA: COMPANY SNAPSHOT, 2025
FIGURE 48 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT, 2025
FIGURE 49 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT, 2025
FIGURE 50 RESEARCH DESIGN
FIGURE 51 KEY DATA FROM SECONDARY SOURCES
FIGURE 52 LIST OF PRIMARY SOURCES
FIGURE 53 KEY INDUSTRY INSIGHTS
FIGURE 54 BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 55 APPROACH 1: REVENUE ESTIMATION OF KEY PLAYERS
FIGURE 56 CAGR PROJECTIONS
FIGURE 57 TOP-DOWN APPROACH
FIGURE 58 DATA TRIANGULATION
FIGURE 59 PARAMETRIC ASSUMPTIONS
